Clinical Trial Update: Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Zemplar (paricalcitol) injection for safety and effectiveness in decreasing iPTH levels in pediatric patients with end-stage r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Secondary Hyperparathyroidism, End Stage Renal Disease | Phase 4 | Status: COMPLETED